Montreal, December 16th, 2014 – The Chairman of the Board, Mr. Léon Gosselin and the President and CEO of CQDM, Ms. Diane Gosselin are pleased to announce the appointment of Ms. Louise Proulx, Chief Development Officer at Therillia as a new member of CQDM’s Board of Directors, of Professor Hans Christian Fibiger, Associate Dean research at the Faculty of Medicine of the University of British Columbia as a new member of the Strategic Orientation Committee and of Patrice Roy, Regional Director, Medical Affairs at Pfizer Canada, since 2014 and a member of the Explore Advisory Committee since 2010 as new chairman of the Committee.
Louise Proulx has thirty years of experience in R &D management. Before being Chief Development Officer at Therillia, she held various scientific positions including Vice President, Product Development at ViroChem Pharma. Following the purchase of this company, she became Vice President and general manager of Vertex Pharmaceuticals (Canada) Inc. To add to her professional expertise, she has previously served as Vice President, Business Development at Genome Quebec and Vice-Principal research at McGill University; Vice President, Therapeutic Drug Developmentat BioChem Pharma Inc. and Vice President, Scientific Affairs at Hoechst Marion Roussel Canada.
In addition to his work as Vice-Dean, Research at the Faculty of Medicine of the University of British Columbia, Professor Hans Christian Fibiger is also scientific director at MedGenesis Therapeutix Inc. since 2011. Prior to this, professor Fibiger served as Vice President of research on the discovery in neuroscience and clinical investigation at Lilly Research Laboratories (LRL) Europe for Eli Lilly and Co. He was also scientific director for Biovail Laboratories International (now Valeant) and Vice President and global Head of neuroscience at Amgen. Mr. Fibiger was a professor at the University of British Columbia from 1970 to 1998 before taking the position of Vice Dean in 2012.
Patrice Roy joined Pfizer Canada in 1996 as Deputy Director of Research in Canada. In 2001, he worked in the Pfizer Pharmaceutical Group (PPG) division at Pfizer Canada as Senior Director, Medical Affairs. In 2006 he was promoted R &D Director for Quebec and Canada’s Atlantic region with the mandate to develop and manage regional scientific partnerships initiatives.
“CQDM is very pleased to be able to count on the involvement of these three experienced members. These outstanding scientists will make an important contribution to the continued development of CQDM” said Diane Gosselin, President and CEO of CQDM.
CQDM is a pharma-based consortium active in pre-competitive research whose mission is to fund the development of innovative tools and technologies to accelerate drug discovery. Unique in the world, CQDM’s business model is based on a collaborative approach where all stakeholders share the costs of biopharmaceutical research and benefit from its results. CQDM also provides a common meeting ground where academia, governments, and the pharmaceutical and biotechnology industries converge to address numerous complex medical challenges. CQDM receives financial support from AstraZeneca, Merck, Pfizer Canada, Boehringer Ingelheim, GlaxoSmithKline, Eli Lilly Canada, Novartis Pharma Canada, Sanofi Canada, as well as from Quebec’s Ministry of Economy, Innovation and Exports (MEIE) and under the Federal government’s Business-Led Networks of Centres of Excellence Program (BL-NCE). For more information, visit us at www.cqdm.org.
Communications and Corporate Development, CQDM
Tel.: (514) 766-6661, ext. 2198